Exegenesis Bio

Exegenesis Bio

  • Founded: 2019
  • Location: Lower Gwynedd, PA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: neovascular AMD
  • Drug types: GEN, MUS, NEU, OPH, GER, HEM, PED
  • Lead product: EXG102-031
  • Product link: https://exegenesisbio.com/pipeline/
  • Funding: $50M Jun 2021 ($120M total)



job board

Short description:

Gene Therapy

Drug notes:

8 additional undisclosed programs RD/Clin0 spinal muscular atrophy, Parkinson's, Bietti's crystalline dystrophy, hemophilia A, phenylketonuria

Long description:

Exegenesis Bio is a multinational company advancing innovative gene and cell therapies focused on three initial areas: central nervous system (CNS), ophthalmology and liver. To advance therapies in these areas, Exegenesis is using their proprietary discovery and manufacturing platforms including AAVarta®, an in-silico evolution discovery platform to design novel AAV capsids using AI technologies. Other platforms include Constellation®, an AI aided gene expression cassette design platform and Progress®, a data-driven protein engineering platform. Together, Exegenesis is advancing a diverse pipeline with lead programs for Spinal Muscular Atrophy and Age-Related Macular Degeneration in early stage clinical trials.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com